Canada Life’s Albany Molecular Research Inc AMRI Stock Holding History

Canada Life’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-31,036	Closed	-$673K	–	2549
2017 Q2	$673K	Buy	31,036 +2,340	+8%	+$42.5K	﹤0.01%	1635
2017 Q1	$403K	Buy	28,696 +2,255	+9%	+$36.9K	﹤0.01%	1760
2016 Q4	$496K	Sell	26,441 -2,233	-8%	-$38K	﹤0.01%	1690
2016 Q3	$473K	Sell	28,674 -4,100	-13%	-$60.7K	﹤0.01%	1680
2016 Q2	$440K	Buy	+32,774	New	+$478K	﹤0.01%	1685

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Canada Life's AMRI Position: Q3 2017 in Review

Canada Life sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 31,036 shares — an estimated $673K sold.

Canada Life first reported a position in AMRI in Q2 2016 and held it in 5 quarters. The position peaked at $673K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Canada Life reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Canada Life sold 31,036 Albany Molecular Research Inc shares in Q3 2017, an estimated $673K.
Canada Life first reported a position in Albany Molecular Research Inc in Q2 2016 and held it in 5 quarters.
Canada Life's Albany Molecular Research Inc position peaked at $673K in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Canada Life's 13F filing for Q3 2017, filed 9 Nov 2017.